Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Cancer Immune Escape and Immunotherapy
share announcement

Cancer Immune Escape and Immunotherapy

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 14108

Special Issue Editors

Dr. Simona Carlomagno

E-Mail
Guest Editor
Department of Experimental Medicine, University of Genoa, 16126 Genova, Italy
Interests: medicine immunology and microbiology biochemistry, genetics and molecular biology multidisciplinary; NK cells; innate immunity
Prof. Dr. Mariella Della Chiesa

E-Mail Website
Guest Editor
Department of Experimental Medicine, University of Genoa, 16126 Genova, Italy
Interests: medicine immunology and microbiology biochemistry, genetics and molecular biology multidisciplinary; NK cells; innate immunity

Special Issue Information

Dear Colleagues,

Understanding the mechanisms behind the failure of the anti-tumor immune response against cancerous cells remains a key point for the development of new successful therapies that are able to hamper cancer progression and dissemination. More and more evidence is delineating an articulated picture of the complex balance in tumor immune-editing that can protect the host against tumor development or promote tumor escape. In different clinical trials, antibody targeting of immune checkpoints mainly expressed by T and NK lymphocytes has presented the possibility to activate the immune system to achieve tumor controls. However, this approach can be limited by the onset of immune-related adverse effects and needs to be combined with other anti-tumor therapies to convert non-responders to responders. Cellular immunotherapy and neoantigen-based vaccines could represent efficient alternatives to develop precision immune-oncology. In this Special Issue, we encourage authors to present recent advances in immunotherapy strategies against hematological and non-hematological tumors as well as new insights into the particular composition of the solid tumor microenvironment that, with its immunosuppressive cytokines and enzyme products; altered nutrients availability; and, in some cases, mesenchymal and collagen barrier molecules, represents a strong limitation to the tumor eradicating function of T and NK cells.

Dr. Simona Carlomagno
Prof. Dr. Mariella Della Chiesa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • cancer escape
  • immune checkpoint
  • tumor microenvironment
  • NK cells
  • T cells
  • neo-antigen
  • vaccines
  • CAR
  • metastasis

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 4439 KiB  
Article
Novel Prognosis and Therapeutic Response Model of Immune-Related lncRNA Pairs in Clear Cell Renal Cell Carcinoma
by Gang Wang, Panhong Liu, Jiangfeng Li, Ke Jin, Xiangyi Zheng and Liping Xie
Vaccines 2022, 10(7), 1161; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10071161 - 21 Jul 2022
Cited by 6 | Viewed by 1868
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is particularly important to accurately judge the prognosis of patients. Since most tumor prediction models depend on the specific expression level of related genes, a better model therefore [...] Read more.
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is particularly important to accurately judge the prognosis of patients. Since most tumor prediction models depend on the specific expression level of related genes, a better model therefore needs to be constructed. To provide an immune-related lncRNA (irlncRNAs) tumor prognosis model that is independent of the specific gene expression levels, we first downloaded and sorted out the data on ccRCC in the TCGA database and screened irlncRNAs using co-expression analysis and then obtained the differently expressed irlncRNA (DEirlncRNA) pairs by means of univariate analysis. In addition, we modified LASSO penalized regression. Subsequently, the ROC curve was drawn, and we compared the area under the curve, calculated the Akaike information standard value of the 5-year receiver operating characteristic curve, and determined the cut-off point to establish the best model to distinguish the high- or low-disease-risk group of ccRCC. Subsequently, we reassessed the model from the perspectives of survival, clinic-pathological characteristics, tumor-infiltrating immune cells, chemotherapeutics efficacy, and immunosuppressed biomarkers. A total of 17 DEirlncRNAs pairs (AL031710.1|AC104984.5, AC020907.4|AC127-24.4,AC091185.1|AC005104.1, AL513218.1|AC079015.1, AC104564.3|HOXB-AS3, AC003070.1|LINC01355, SEMA6A-AS1|CR936218.1, AL513327.1|AS005785.1, AC084876.1|AC009704.2, IGFL2-AS1|PRDM16-DT, AC011462.4|MMP25-AS1, AL662844.3I|TGB2-AS1, ARHGAP27P1|AC116914.2, AC093788.1|AC007098.1, MCF2L-AS1|AC093001.1, SMIM25|AC008870.2, and AC027796.4|LINC00893) were identified, all of which were included in the Cox regression model. Using the cut-off point, we can better distinguish patients according to different factors, such as survival status, invasive clinic-pathological features, tumor immune infiltration, whether they are sensitive to chemotherapy or not, and expression of immunosuppressive biomarkers. We constructed the irlncRNA model by means of pairing, which can better eliminate the dependence on the expression level of the target genes. In other words, the signature established by pairing irlncRNA regardless of expression levels showed promising clinical prediction value. Full article
(This article belongs to the Special Issue Cancer Immune Escape and Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

20 pages, 1750 KiB  
Review
NK Cell-Based Immunotherapy in Colorectal Cancer
by Mariella Della Chiesa, Chiara Setti, Chiara Giordano, Valentina Obino, Marco Greppi, Silvia Pesce, Emanuela Marcenaro, Mariangela Rutigliani, Nicoletta Provinciali, Laura Paleari, Andrea DeCensi, Simona Sivori and Simona Carlomagno
Vaccines 2022, 10(7), 1033; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10071033 - 28 Jun 2022
Cited by 11 | Viewed by 4136
Abstract
Human Natural Killer (NK) cells are all round players in immunity thanks to their powerful and immediate response against transformed cells and the ability to modulate the subsequent adaptive immune response. The potential of immunotherapies based on NK cell involvement has been initially [...] Read more.
Human Natural Killer (NK) cells are all round players in immunity thanks to their powerful and immediate response against transformed cells and the ability to modulate the subsequent adaptive immune response. The potential of immunotherapies based on NK cell involvement has been initially revealed in the hematological setting but has inspired the design of different immune tools to also be applied against solid tumors, including colorectal cancer (CRC). Indeed, despite cancer prevention screening plans, surgery, and chemotherapy strategies, CRC is one of the most widespread cancers and with the highest mortality rate. Therefore, further efficient and complementary immune-based therapies are in urgent need. In this review, we gathered the most recent advances in NK cell-based immunotherapies aimed at fighting CRC, in particular, the use of monoclonal antibodies targeting tumor-associated antigens (TAAs), immune checkpoint blockade, and adoptive NK cell therapy, including NK cells modified with chimeric antigen receptor (CAR-NK). Full article
(This article belongs to the Special Issue Cancer Immune Escape and Immunotherapy)
►▼ Show Figures

Figure 1

13 pages, 1752 KiB  
Review
Exploring the Impact of TREM2 in Tumor-Associated Macrophages
by Darya Khantakova, Simone Brioschi and Martina Molgora
Vaccines 2022, 10(6), 943; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10060943 - 14 Jun 2022
Cited by 11 | Viewed by 5862
Abstract
Tumor-associated macrophages (TAMs) represent a key component of the tumor microenvironment and are generally associated with immunosuppression and poor prognosis. TREM2 is a transmembrane receptor of the immunoglobulin superfamily expressed in myeloid cells. TREM2 has been extensively studied in microglia and neurodegenerative diseases [...] Read more.
Tumor-associated macrophages (TAMs) represent a key component of the tumor microenvironment and are generally associated with immunosuppression and poor prognosis. TREM2 is a transmembrane receptor of the immunoglobulin superfamily expressed in myeloid cells. TREM2 has been extensively studied in microglia and neurodegenerative diseases and recently emerged as a marker of pro-tumorigenic macrophages. The accumulation of TREM2-expressing TAMs was reported across numerous cancer patients and tumor models. TREM2 genetic blockade or TREM2 targeting with antibodies resulted in improved tumor control, enhanced response to anti-PD1, and significant changes in the tumor immune landscape. Preclinical studies paved the way for an ongoing clinical trial with a TREM2 depleting antibody and inspired further exploration of TREM2 targeting therapies. Here, we review the current knowledge about the impact of TREM2 in cancer, with an emphasis on the TREM2+ macrophage signature across different cancer types, the contribution of TREM2 to TAM phenotype and function, and the promising effects of TREM2 modulation. Full article
(This article belongs to the Special Issue Cancer Immune Escape and Immunotherapy)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

9 pages, 539 KiB  
Viewpoint
Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?
by Massimo Vitale and Monica Parodi
Vaccines 2021, 9(10), 1144; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9101144 - 07 Oct 2021
Cited by 4 | Viewed by 1570
Abstract
Natural Killer (NK) cells are becoming an ever more promising tool to design new anti-tumor strategies. However, two major issues are still a challenge to obtain versatile and effective NK-based therapies: the way to maximize the persistency of powerful NK effectors in the [...] Read more.
Natural Killer (NK) cells are becoming an ever more promising tool to design new anti-tumor strategies. However, two major issues are still a challenge to obtain versatile and effective NK-based therapies: the way to maximize the persistency of powerful NK effectors in the patient, and the way to overcome the multiple escape mechanisms that keep away or suppress NK cells at the tumor site. In this regard, targeting the hypoxia-inducible factors (HIFs), which is important for both tumor progression and immune suppression, may be an opportunity. Especially, in the context of the ongoing studies focused on more effective NK-based therapeutic products. Full article
(This article belongs to the Special Issue Cancer Immune Escape and Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop